Loading viewer...
investor_presentation
Format: PDF investor_presentation
Conference Call PresentationYear-end Report 2021 Lund, February 3, 2022
Conference Call PresentationYear-end Report 2021 Lund, February 3, 2022
Thispresentationmaycontaincertainforward-lookingstatementsandforecastsbasedonourcurrentexpectationsandbeliefsregardingfutureeventsandaresubjecttosignificantuncertaintiesandriskssincetheyrelatetoeventsanddependoncircumstancesthatwilloccurinthefuture.Someoftheseforward-lookingstatements,bytheirnature,couldhaveanimpactonHansaBiopharma’sbusiness,financialconditionandresultsofoperations[orthatofitsparent,affiliate,orsubsidiarycompanies].Termssuchas“anticipates”,“assumes”,“believes”,“can”,“could”,“estimates”,“expects”,“forecasts”,“intends”,“may”,“might”,“plans”,“should”,“projects”,“will”,“would”or,ineachcase,theirnegative,orothervariationsorcomparableterminologyareusedtoidentifyforward-lookingstatements.Thereareanumberoffactorsthatcouldcauseactualresultsanddevelopmentstodiffermateriallyfromthoseprojected,whetherexpresslyorimpliedly,inaforward-lookingstatementoraffecttheextenttowhichaparticularprojectionisrealized.Suchfactorsmayinclude,butarenotlimitedto,changesinimplementationofHansaBiopharma’sstrategyanditsabilitytofurthergrow;risksanduncertaintiesassociatedwiththedevelopmentand/orapprovalofHansaBiopharma’sproductcandidates;ongoingclinicaltrialsandexpectedtrialresults;theabilitytocommercializeimlifidaseifapproved;changesinlegalorregulatoryframeworks,requirements,orstandards;technologychangesandnewproductsinHansaBiopharma’spotentialmarketandindustry;theabilitytodevelopnewproductsandenhanceexistingproducts;theimpactofcompetition,changesingeneraleconomyandindustryconditionsandlegislative,regulatoryandpoliticalfactors.Thefactorssetforthabovearenotexhaustiveandadditionalfactorscouldadverselyaffectourbusinessandfinancialperformance.Weoperateinaverycompetitiveandrapidlychangingenvironment,anditisnotpossibletopredictallfactors,norcanweassesstheimpactofallfactorsonourbusinessortheextenttowhichanyfactor,orcombinationoffactors,maycauseactualresultstodiffermateriallyfromthosecontainedinanyforward-lookingstatements.Giventheserisksanduncertainties,investorsshouldnotplaceunduerelianceonforward-lookingstatementsasapredictionofactualresults.HansaBiopharmaexpresslydisclaimsanyobligationtoupdateorreviseanyforward-lookingstatementstoreflectchangesinunderlyingassumptionsorfactors,newinformation,futureeventsorotherwise,anddisclaimsanyexpressorimpliedrepresentationsorwarrantiesthatmayarisefromanyforward-lookingstatements.Youshouldnotrelyupontheseforward-lookingstatementsafterthedateofthispresentation.Forward-looking statements
Preview truncated — download the full document for the complete content.
conference
17 Pages
Hansa Biopharma Investor Presentation — April 2024
investor_presentationinvestor_presentation
99 Pages
investor_presentation
21 Pages
Sherritt International Corporation
Karyopharm Therapeutics Investor Presentation — December 2021
investor_presentationinvestor_presentation
139 Pages
Karyopharm Therapeutics Inc.
Oportun Financial Investor Presentation — March 2020
investor_presentationinvestor_presentation
43 Pages
Oportun Financial Corporation